ZYME
Zymeworks·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ZYME
Zymeworks Inc.
A company that develops multifunctional biotherapeutics for the treatment of cancer
108 Patriot Drive — Suite A, Middletown, Delaware 19709
--
Zymeworks Inc., was incorporated under the laws of the State of Delaware in June 2022. Zymeworks is a clinical-stage biopharmaceutical company that develops a diverse pipeline of novel multifunctional biotherapeutic drugs to improve the standard of care for difficult-to-treat diseases. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab, is a novel Azymetric HER2 targeting bispecific antibody currently being evaluated in multiple Phase 1, 2 and pivotal clinical trials worldwide as a targeted therapy option for patients with solid tumors expressing HER 2. Zymeworks' second clinical candidate, Zanidatamab Zovodotin (ZW49), is a novel bispecific HER2 targeted antibody drug conjugate currently in Phase 1 clinical development that combines Zanidatamab's unique design and antibody framework with Zymeworks' proprietary ZymeLink connector and cytotoxin. Zymeworks is also advancing an in-depth preclinical pipeline in oncology (including immuno-oncology drugs) and other therapeutic areas. In addition, through strategic partnerships with global biopharmaceutical companies, it is leveraging its therapeutic platform 3.
Earnings Call
Q1/2025
Estimate EPS-0.73
Actual EPS-0.3
Estimate Revenue20.65M
Actual Revenue27.11M
Zymeworks Q1 2025: Key Contradictions in ADC Strategies, Partnership Revenues, and Clinical Trials
May 19,2025 01:57
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ZYME has released its 2025 Q3 earnings. EPS was reported at -0.26, versus the expected -0.43, beating expectations. The chart below visualizes how ZYME has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ZYME has released its 2025 Q3 earnings report, with revenue of 27.61M, reflecting a YoY change of 72.59%, and net profit of -19.60M, showing a YoY change of 34.33%. The Sankey diagram below clearly presents ZYME's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
